Skip to content

LD-Oncologic

Active
Private limited companyfounded 2013active for 13 yearsRue des Ecoles 7, 5520 Onhaye, BelgiumKBO/BCE: BE 0533.702.512
Summary

LD-Oncologic has been active since 2013 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €140,314 and a net result of €39,623. Equity is growing by about 30% per year across the filed financial years. The computed 12-month bankruptcy probability is 0.1% (very low).

History

On 26 April 2013, LD-Oncologic was incorporated.1 In 2024 the company took the name LD-Oncologic.2 Total assets went from €179,115 in 2018 to €268,450 in 2025.3

  1. 1KBO register
  2. 2Belgian Official Gazette, 04-01-2024
  3. 3National Bank, annual accounts 2018 and 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-07-2027
2026
15-07
NBB filing Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial Highest result from 2018 to 2025net €39,623 ▲14%
Operating result €62,191, net result €39,623, both a record.
20-08
NBB filing Annual accounts filed
financial year 2024 · micro format · 20 days late
2024
31-12
Financial Equity above €100,000equity €113,459 ▲44.1%
A profit in every financial year since 2018 builds equity to €113,459.
30-08
NBB filing Annual accounts filed
financial year 2023 · micro format · 30 days late
04-01
Gazette deed Resignations: Christophe LONCHAY (manager) and Virginie DI SILVERIO (manager)
Appointments: Christophe LONCHAY (director) and Virginie DI SILVERIO (director) · Capital conversion · Reserve release14 facts ▸
  • Other provision, “société à responsabilité limitée” (deed in French)
  • Capital conversion, “compte de capitaux propres statutairement indisponible” (deed in French)
  • Reserve release, “suppression, montant correspondant disponible pour distribution” (deed in French)
  • Other provision, “rapport modification de l'objet, rapport de l'organe d'administration justifiant en détail la modification proposée” (deed in French)
  • Purpose change
  • Name change, LD-Oncologic
  • Amendment of the articles
  • Director resignation, Christophe LONCHAY (manager)
  • Director resignation, Virginie DI SILVERIO (manager)
  • Director appointment, Christophe LONCHAY (director (not named in the articles))
  • Director appointment, Virginie DI SILVERIO (director (not named in the articles))
  • Registered office clause, “5520-Onhaye,Rue des Ecoles,7” (deed in French)
  • +2 further facts in this act
2023
29-08
NBB filing Annual accounts filed
financial year 2022 · micro format · 29 days late
2022
25-08
NBB filing Annual accounts filed
financial year 2021 · micro format · 25 days late
2021
26-08
NBB filing Annual accounts filed
financial year 2020 · micro format · 26 days late
2020
14-07
NBB filing Annual accounts filed
financial year 2019 · micro format
2019
31-12
Financial Weakest financial yearnet €5,676 ▼74.3%
Net result drops to €5,676, the lowest in the series; recovery starts the following year.
11-07
NBB filing Annual accounts filed
financial year 2018 · micro format
2018
03-07
NBB filing Annual accounts filed
financial year 2017 · micro format
2017
28-07
NBB filing Annual accounts filed
financial year 2016 · micro format
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 13 annual accounts filed, the latest 10 are here; all 13 are under Financials.
1 of 3 deeds read
About the unread acts

Of the 3 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.